Trade ACRV anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Acrivon Therapeutics, Inc. (ACRV) is trading at US$2.08, down 3.49% today as of Aug 28, 11:44 EDT. The company has a market capitalisation of US$94.71M. Over the past 52 weeks, ACRV has traded between US$1.27 and US$3.56. On Syfe you can trade ACRV with $0 commission and add it to your watchlist.
| Previous close | US$2.15 |
|---|---|
| Market cap | US$94.71M |
| 52-week range | US$1.27 – US$3.56 |
| Volume | 188.24K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Year: 2022
Acrivon Therapeutics Q1 Loss Narrows
May 13, 9:14 PM · MT Newswires
Acrivon Therapeutics, Inc. (ACRV) stock is trading at US$2.08, -3.49% from the previous close of US$2.15.
The market cap for Acrivon Therapeutics, Inc. (ACRV) stock is approximately US$94.71M.
The 52-week high for Acrivon Therapeutics, Inc. (ACRV) stock is US$3.56.
The 52-week low for Acrivon Therapeutics, Inc. (ACRV) stock is US$1.27.
Acrivon Therapeutics, Inc. (ACRV) does not currently pay a dividend.
Stay on top of ACRV
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
